High precision laboratory rodent dry powder nose-only inhalation exposure combined by pre-clinical pulmonary models (asthma, COPD, fibrosis)

Pre-clinical Hungarian CRO offers dry powder inhalation exposure technology for pre-clinical pharmacokinetics (PK) and pharmacodynamics (PD) studies. The service allows the requestor to assess the efficacy of his active pharmaceutical ingredient (API) on a pulmonary animal model following acute or repeated nose-only dry powder inhalation administration. The company is looking for partners for research or technical cooperation.
The SME operates as pre-clinical CRO in Hungary. It offers support for research groups or pharmaceutical companies that are active or interested in the development of inhalation drug formulations, especially as dry powder ones. The company is specialized in carrying out animal models on immune-inflammation including inflammatory pulmonary disorders like asthma, COPD (chronic obstructive pulmonary disease) or fibrosis. The company has laboratory rodent inhalation system for controlled dose inhalation exposure. The staff has been active on respiratory pharmacology for several decades and gained expertise in a multinational R&D organisation. The company has broad range of scientific equipment to evaluate readouts from the experimental samples. Research groups usually find difficult organisations (e.g. preclinical CROs) where the fine dosed dry powder inhalation technology and pre-clinical animal models on pulmonary disease indications are up and running together. The Hungarian SME offers solution and support to these groups. The company is looking for SMEs and research groups to work together in the frame of research/technical cooperation.
Type (e.g. company, R&D institution…), field of industry and Role of Partner Sought: 
- Type of partner sought: Research institute, SME. - Specific area of activity of the partner: Drug R&D, air pollution toxicology. - Task to be performed: Drug pre-formulation before sending it to inhalation exposure.
Stage of Development: 
Already on the market
IPR Status: 
External code: